FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965663170> ?p ?o ?g. }

• W2965663170 abstract "2569 Background: ADI-PEG20 is an enzyme that degrades arginine (Arg), an amino acid relevant to biosynthetic pathways of normal and malignant cells. It has shown tolerability and activity in several solid tumors. Preclinical studies have shown that Arg deprivation by ADI-PEG 20 in cancer cells induces autophagy, caspase-independent apoptosis, and potentiates DOC-induced cytotoxicity in prostate cancer (PC) models. A phase I trial (standard 3+3 design) of ADI-PEG20 (IM weekly) plus DOC (IV on day 1 q 3 weeks) was conducted to assess feasibility and safety of the combination. Methods: Eligible pts were >18 years of age, had advanced malignant solid tumors, adequate end organ function, and performance status (PS) 0-2. ADI-PEG 20 was escalated over 4 dose levels (4.5, 9, 18, 36 mg/m2). DOC dose was 75 mg/m2. Dose limiting toxicity (DLT) was defined as any of the following in cycle 1: thrombocytopenia [grade (Gr) 3 with bleeding/transfusion, or Gr 4]; neutropenia with fever or documented infection attributable to ADI PEG20; or any ≥ Gr 3 non-heme toxicity related to study drug except alopecia. Allergic reaction associated with DOC was not considered a DLT. Serum levels of Arg were serially measured. Results: 18 pts were accrued: median age, 64.5 yrs; male, 83%; PS 0, 72%. Most common tumors were NSCLC (8), PC (3), and tongue cancer (TC) (2). Median number of prior systemic therapies was 3. One DLT was seen in dose level 1 (urticarial rash) requiring expansion of that dose level to 6 pts. No additional DLTs attributable to ADI PEG20 were seen. Serious adverse events (all expected and attributed to DOC) were recorded in 11/18 pts, including Gr IV neutropenia (6, 33%) and Gr IV anemia (2, 11%). There were 2 on-study deaths unrelated to protocol therapy. In 11 pts with evaluable disease, 1 with TC had a partial response (PR), 6 had stable disease (SD) (3 NSCLC, 2 PC, 1 TC). Arg levels decreased in the 1st cycle for 6/11 pts with available data, including 2 with SD, and 1 with PR. Conclusions: The combination of ADI PEG20 and DOC is feasible with reasonable tolerability in this heavily pre-treated cohort. Full doses of both agents were achievable: ADI-PEG 20 at 36mg/m2 with DOC 75 mg/m2. An expansion cohort of castration resistant PC pts is now accruing at this recommended dose. Clinical trial information: NCT01497925." @default.
• W2965663170 created "2019-08-13" @default.
• W2965663170 creator A5006055249 @default.
• W2965663170 creator A5007808102 @default.
• W2965663170 creator A5015755231 @default.
• W2965663170 creator A5016546967 @default.
• W2965663170 creator A5029586363 @default.
• W2965663170 creator A5033098542 @default.
• W2965663170 creator A5036091074 @default.
• W2965663170 creator A5066051408 @default.
• W2965663170 creator A5075799959 @default.
• W2965663170 creator A5077352149 @default.
• W2965663170 creator A5077391276 @default.
• W2965663170 creator A5090328595 @default.
• W2965663170 date "2013-05-20" @default.
• W2965663170 modified "2023-09-27" @default.
• W2965663170 title "Phase I trial of ADI-peg 20 plus docetaxel (DOC) in patients (pts) with advanced solid tumors." @default.
• W2965663170 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.2569" @default.
• W2965663170 hasPublicationYear "2013" @default.
• W2965663170 type Work @default.
• W2965663170 sameAs 2965663170 @default.
• W2965663170 citedByCount "0" @default.
• W2965663170 crossrefType "journal-article" @default.
• W2965663170 hasAuthorship W2965663170A5006055249 @default.
• W2965663170 hasAuthorship W2965663170A5007808102 @default.
• W2965663170 hasAuthorship W2965663170A5015755231 @default.
• W2965663170 hasAuthorship W2965663170A5016546967 @default.
• W2965663170 hasAuthorship W2965663170A5029586363 @default.
• W2965663170 hasAuthorship W2965663170A5033098542 @default.
• W2965663170 hasAuthorship W2965663170A5036091074 @default.
• W2965663170 hasAuthorship W2965663170A5066051408 @default.
• W2965663170 hasAuthorship W2965663170A5075799959 @default.
• W2965663170 hasAuthorship W2965663170A5077352149 @default.
• W2965663170 hasAuthorship W2965663170A5077391276 @default.
• W2965663170 hasAuthorship W2965663170A5090328595 @default.
• W2965663170 hasConcept C10138342 @default.
• W2965663170 hasConcept C126322002 @default.
• W2965663170 hasConcept C141071460 @default.
• W2965663170 hasConcept C143998085 @default.
• W2965663170 hasConcept C162324750 @default.
• W2965663170 hasConcept C2776694085 @default.
• W2965663170 hasConcept C2781190966 @default.
• W2965663170 hasConcept C54400483 @default.
• W2965663170 hasConcept C71924100 @default.
• W2965663170 hasConceptScore W2965663170C10138342 @default.
• W2965663170 hasConceptScore W2965663170C126322002 @default.
• W2965663170 hasConceptScore W2965663170C141071460 @default.
• W2965663170 hasConceptScore W2965663170C143998085 @default.
• W2965663170 hasConceptScore W2965663170C162324750 @default.
• W2965663170 hasConceptScore W2965663170C2776694085 @default.
• W2965663170 hasConceptScore W2965663170C2781190966 @default.
• W2965663170 hasConceptScore W2965663170C54400483 @default.
• W2965663170 hasConceptScore W2965663170C71924100 @default.
• W2965663170 hasLocation W29656631701 @default.
• W2965663170 hasOpenAccess W2965663170 @default.
• W2965663170 hasPrimaryLocation W29656631701 @default.
• W2965663170 hasRelatedWork W2077602909 @default.
• W2965663170 hasRelatedWork W2081321945 @default.
• W2965663170 hasRelatedWork W2124733560 @default.
• W2965663170 hasRelatedWork W2245320394 @default.
• W2965663170 hasRelatedWork W2268825647 @default.
• W2965663170 hasRelatedWork W2336100460 @default.
• W2965663170 hasRelatedWork W2408189227 @default.
• W2965663170 hasRelatedWork W2426974342 @default.
• W2965663170 hasRelatedWork W2515015083 @default.
• W2965663170 hasRelatedWork W2597270260 @default.
• W2965663170 hasRelatedWork W2604130272 @default.
• W2965663170 hasRelatedWork W2653565671 @default.
• W2965663170 hasRelatedWork W2891430325 @default.
• W2965663170 hasRelatedWork W2892252583 @default.
• W2965663170 hasRelatedWork W3166453143 @default.
• W2965663170 isParatext "false" @default.
• W2965663170 isRetracted "false" @default.
• W2965663170 magId "2965663170" @default.
• W2965663170 workType "article" @default.